Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y, Weygant N, Qu D, May R, Berry WL, Yao J, Chandrakesan P, Zheng W, Zhao L, Zhao KL, Drake M, Vega KJ, Bronze MS, Tomasek JJ, An G, Houchen CW.
Ge Y, et al. Among authors: zhao l, zhao kl.
Int J Cancer. 2018 Sep 1;143(5):1162-1175. doi: 10.1002/ijc.31400. Epub 2018 Apr 16.
Int J Cancer. 2018.
PMID: 29577277
Free PMC article.